HAEMOPHILIA B
Clinical trials for HAEMOPHILIA B explained in plain language.
Never miss a new study
Get alerted when new HAEMOPHILIA B trials appear
Sign up with your email to follow new studies for HAEMOPHILIA B, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Japanese hemophilia b patients monitored on refixia – no surprises found
Disease control CompletedThis study followed 28 people with hemophilia B in Japan who were already prescribed Refixia as part of their normal care. Researchers tracked side effects, bleeding episodes, and quality of life to confirm the drug's safety and effectiveness over time. The study did not test a n…
Matched conditions: HAEMOPHILIA B
Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for hemophilia b: trial tests Long-Acting clotting factor in chinese patients
Disease control CompletedThis study tested a medicine called nonacog beta pegol (N9-GP) in 30 Chinese men with moderate to severe hemophilia B. The medicine is injected into a vein to help blood clot and prevent or treat bleeding episodes. The trial lasted about 12-16 months and checked how well the medi…
Matched conditions: HAEMOPHILIA B
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Weekly shot could help kids with hemophilia b avoid bleeding
Disease control CompletedThis study tested a new long-acting factor IX drug (nonacog beta pegol) in 25 children with hemophilia B. The drug is given as a weekly injection to prevent bleeding episodes. The main goal was to check safety and whether the body develops antibodies that block the treatment. Res…
Matched conditions: HAEMOPHILIA B
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New hope for kids with hemophilia b: Long-Acting drug shows promise in preventing bleeds
Disease control CompletedThis study tested a new long-acting clotting factor drug called nonacog beta pegol in 54 young children with hemophilia B who had not been treated before. The drug was given regularly to prevent bleeding episodes and also to treat any bleeds that occurred. The main goal was to se…
Matched conditions: HAEMOPHILIA B
Phase: PHASE3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC